



**Vivimed**

Date: 14/02/2017

To  
BSE Limited  
P.J.Towers, Dalal Street,  
Mumbai – 400001

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

**BSE - Code : 532660**

**NSE- Symbol: VIVIMEDLAB**

Dear Sir/Madam

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.**

The Board of Directors of the Company at its meeting held on February 14, 2017 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter & Nine months ended December 31, 2016 attached herewith;
2. Auditors's Limited Review Report on the Un -audited Financial Statements of the Company for the for the Quarter & Nine months ended December 31, 2016.

An earnings related presentation including business highlights will be uploaded on the company's website [www.vivimedlabs.com](http://www.vivimedlabs.com)

You are requested to take note of the above.

Yours faithfully

**For Vivimed Labs Limited**

  
**SANTOSH VARALWAR**  
**MANAGING DIRECTOR**



Vivimed Labs Ltd. (Corporate Office)

CIN : LQ2411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

[contact@vivimedlabs.com](mailto:contact@vivimedlabs.com) [www.vivimedlabs.com](http://www.vivimedlabs.com)



**VIVIMED LABS LIMITED**  
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS ENDED 31<sup>ST</sup> DEC 2016

Sl. No.	Particulars	Quarter Ended			9 Months Ended		Previous Year ended 31.03.2016 (Audited)
		31.12.2016 (Unaudited)	30.09.2016 (Unaudited)	31.12.2015 (Unaudited)	31.12.2016 (Unaudited)	31.12.2015 (Unaudited)	
1	<b>Income From Operations</b>						
	(a) Net Sales / Income from Operations (Net of Excise Duty)						
	(b) Other Operating Income	36,003.30	29,836.48	32,991.12	102,522.82	99,846.77	134,562.99
	<b>Total Income From Operations (Net)</b>	36,311.19	29,928.57	33,187.89	103,099.39	100,639.24	135,643.97
	a. Cost of Raw Materials Consumed	13,827.91	14,290.03	15,023.74	44,893.30	45,845.33	60,969.16
	b. Purchase of Stock in Trade						
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade						
	d. Employee Benefit Expenses	(1,291.63)	(862.15)	43.70	(1,735.54)	(12.72)	1,435.62
	e. Depreciation and Amortisation Expenses	5,008.86	4,141.09	3,825.02	14,164.71	12,144.26	17,694.25
	f. Other Expenditure	1,547.07	1,493.79	1,545.04	4,568.07	4,662.28	6,139.34
2	<b>Total Expenses</b>	8,457.43	6,237.42	8,169.44	22,661.36	23,496.57	31,255.74
		27,549.64	25,300.18	28,606.94	84,551.89	86,135.72	117,494.10
3	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	8,761.55	4,628.39	4,580.95	18,547.50	14,503.52	18,149.87
4	Other Income						
5	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	8,761.55	4,628.39	4,580.95	18,547.50	14,503.52	18,149.87
6	Finance Costs	1,733.95	1,494.21	1,921.72	4,748.99	5,705.83	8,156.63
7	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	7,027.60	3,134.18	2,659.23	13,798.51	8,797.69	9,993.24
8	Exceptional items						
9	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	7,027.60	3,134.18	2,659.23	13,798.51	8,797.69	9,993.24
10	Tax Expenses	1,856.79	448.96	357.54	3,099.36	1,691.04	1,625.93
11	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	5,170.81	2,685.22	2,301.69	10,699.15	7,106.65	8,367.32
12	Extraordinary Items (net of tax expenses Rs.....lacs)						
13	<b>Net Profit / Loss for period (11 - 12)</b>	5,170.81	2,685.22	2,301.69	10,699.15	7,106.65	8,367.32
14	Share of Profit / (Loss) of associates						
15	Minority Interest						
16	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	5,170.81	2,685.22	2,301.69	10,699.15	7,106.65	8,367.32
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year						
19	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)						
	(a) Basic	6.38	3.31	2.84	13.21	8.77	10.33
	(b) Diluted	6.19	3.22	2.76	12.81	8.51	10.02

- The above Consolidated Unaudited Financial Results for the Quarter & 9 Months ended DECEMBER 31<sup>ST</sup> 2016 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 14.02.2017.
- The results shown above for all the past quarters and 9 months ended 31.12.2015 and for FY 16 are of unaudited nature. Hence the figures are not comparable to those of the quarter ended 31.12.2015.
- The divestiture of Korsehen business has been recognised.
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.
- The company has calculated depreciation as per the provisions under companies act of 2013.

Place : Hyderabad  
Date : 14.02.2017

For VIVIMED LABS LIMITED  
(SANTOSH VARALWAR)  
MANAGING DIRECTOR





**VIVIMED LABS LIMITED**

**SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED**

*Rs. in Lacs*

Particulars	3 Months Ended			9 Months Ended		FY 16
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)						
a. Specialty Chemicals Business	7,061.54	8,106.78	8,685.91	23,670.17	27,691.50	37,141.35
b. Pharma Business	28,941.76	21,729.71	24,305.20	78,852.65	72,155.28	97,421.63
<b>Total</b>	<b>36,003.30</b>	<b>29,836.49</b>	<b>32,991.12</b>	<b>102,522.82</b>	<b>99,846.77</b>	<b>134,562.98</b>
Less, Inter Segment Revenue						
<b>Net sales / Income from Operations</b>	<b>36,003.30</b>	<b>29,836.49</b>	<b>32,991.12</b>	<b>102,522.82</b>	<b>99,846.77</b>	<b>134,562.98</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>						
a. Specialty Chemicals Business	1,419.05	2,070.50	1,733.17	5,008.70	5,584.63	6,796.84
b. Pharma Business	7,342.50	2,557.89	2,847.78	13,538.80	8,918.89	11,353.02
<b>Total</b>	<b>8,761.55</b>	<b>4,628.39</b>	<b>4,580.95</b>	<b>18,547.50</b>	<b>14,503.52</b>	<b>18,149.86</b>
Less: 1. Interest	1,733.95	1,494.21	1,921.72	4,748.99	5,705.83	8,156.63
2. Other Un-allocable Expenditure						
3. Un-allocable Income						
<b>Total Profit Before Tax</b>	<b>7,027.60</b>	<b>3,134.18</b>	<b>2,659.23</b>	<b>13,798.51</b>	<b>8,797.69</b>	<b>9,993.23</b>
<b>3. Capital Employed</b>						
a. Specialty Chemicals Business	72,216.23	71,716.20	75,577.24	72,216.23	75,577.24	84,539.58
b. Pharma Business	93,253.78	87,253.78	67,345.35	93,253.78	67,345.35	70,862.31
	165,470.01	158,969.98	142,922.59	165,470.01	142,922.59	155,401.89
<b>4</b>						
Segment Assets	214,624.85					
Segment Liabilities	143,790.05					

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR

Place : Hyderabad  
Date : 14.02.2017



**VIVIMED LABS LIMITED**  
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS ENDED 31<sup>ST</sup> DEC 2016

Sl. No.	Particulars	Quarter Ended				9 Months Ended		Previous Year ended 31.03.2016
		31.12.2016 (Amalgomated Unaudited)	30.09.2016 (Unaudited)	31.12.2015 (Unaudited)	31.12.2016 (Amalgomated Unaudited)	31.12.2015 (Unaudited)	(Audited)	
1	Income From Operations							
	(a) Net Sales / Income from Operations (Net of Excise Duty)	13,952.42	6,771.22	8,005.34	34,375.36	23,985.78	31,939.36	
	(b) Other Operating Income	51.14	0.34	1.03	69.87	31.21	98.38	
	Total Income From Operations (Net)	14,003.56	6,771.56	8,006.38	34,445.23	24,016.99	32,037.74	
	a. Cost of Raw Materials Consumed	3,960.25	2,746.31	2,877.17	14,871.67	9,193.57	12,467.66	
	b. Purchase of Stock in Trade							
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(138.23)	236.63	318.20	(689.71)	699.78	686.79	
	d. Employee Benefit Expenses	999.42	557.60	619.67	3,039.34	1,754.29	2,399.35	
	e. Depreciation and Amortisation Expenses	755.67	441.25	447.53	2,120.34	1,344.79	1,879.24	
	f. Other Expenditure	1,859.84	1,421.33	1,993.65	5,993.46	5,720.31	7,864.80	
2	Total Expenses	7,436.95	5,403.12	6,256.23	25,335.09	18,712.75	25,297.84	
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional Items (1 - 2)	6,566.61	1,368.45	1,750.15	9,110.13	5,304.24	6,739.90	
4	Other Income							
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional Items (3 - 4)	6,566.61	1,368.45	1,750.15	9,110.13	5,304.24	6,739.90	
6	Finance Costs	1,362.26	1,157.77	1,410.94	3,923.07	4,405.90	5,605.93	
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional Items (5 - 6)	5,204.35	210.68	339.21	5,187.06	898.34	1,133.96	
8	Exceptional Items							
9	Profit / Loss from ordinary activities before Tax (7 - 8)	5,204.35	210.68	339.21	5,187.06	898.34	1,133.96	
10	Tax Expenses	1,184.77	42.13	67.84	1,283.36	165.69	321.16	
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	4,019.58	168.55	271.37	3,903.70	732.65	812.80	
12	Extraordinary Items (net of tax expenses Rs...../Lacs)							
13	Net Profit / Loss for period (11 - 12)	4,019.58	168.55	271.37	3,903.70	732.65	812.80	
14	Share of Profit / (Loss) of associates							
15	Minority Interest							
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	4,019.58	168.55	271.37	3,903.70	732.65	812.80	
17	Pool up Equity Share Capital (face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year							
19	Earnings per Share (before Extraordinary Items) (a) Rs./, each (not annualised)	4.96	0.21	0.33	4.82	0.90	1.00	
	(a) Basic							
	(b) Diluted	4.81	0.20	0.32	4.67	0.88	0.97	

1. The above Unaudited Standalone Unaudited Financial Results for the Quarter & 9 Months ended December 31<sup>st</sup> 2016 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 14<sup>th</sup> February 2017

2. The results shown above for all the past quarters and 9 months ended 31.12.2015 and for FY 16 are of unaudited nature. Hence the figures are not comparable to those of the quarter ended 31.12.2016

3. The directors of Vivimed Labs have been recognised.

4. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website [www.vivimedlabs.com](http://www.vivimedlabs.com) and also on BSE & NSE websites.

5. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

6. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

7. (i) Creative Healthcare Private Limited, (ii) Kiran Sahen Private Limited, (iii) Octonus Nobel Labs Private Limited, (iv) Vivimed Labs (Asteris) Pvt Limited have been amalgamated with Vivimed Labs Ltd

For VIVIMED LABS LIMITED

(SANTOSH VARADWARI)  
MANAGING DIRECTOR





**VIVIMED LABS LIMITED**  
**SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED**

Particulars	3 Months Ended			9 Months Ended			FY 16 31-03-2016 (Audited)
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015		
	Amalgamated Unaudited	(Unaudited)	(Unaudited)	Amalgamated Unaudited	(Unaudited)		
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)							
a. Specialty Chemicals Business	4,227.12	4,500.61	6,052.85	14,158.33	18,033.57	24,113.40	
b. Pharma Business	9,725.30	2,270.61	1,952.49	20,217.03	5,952.21	7,825.96	
<b>Total</b>	<b>13,952.42</b>	<b>6,771.22</b>	<b>8,005.34</b>	<b>34,375.36</b>	<b>23,985.78</b>	<b>31,939.36</b>	
Less, Inter Segment Revenue							
<b>Net sales / Income from Operations</b>	<b>13,952.42</b>	<b>6,771.22</b>	<b>8,005.34</b>	<b>34,375.36</b>	<b>23,985.78</b>	<b>31,939.36</b>	
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>							
a. Specialty Chemicals Business	1,013.92	1,020.92	1,513.78	3,213.31	4,734.23	5,918.33	
b. Pharma Business	5,552.70	347.53	236.37	5,896.82	570.01	821.57	
<b>Total</b>	<b>6,566.61</b>	<b>1,368.45</b>	<b>1,750.15</b>	<b>9,110.13</b>	<b>5,304.24</b>	<b>6,739.90</b>	
Less: 1. Interest	1,362.26	1,157.77	1,410.94	3,923.07	4,405.90	5,605.93	
2. Other Un-allocable Expenditure							
3. Un-allocable Income							
<b>Total Profit Before Tax</b>	<b>5,204.35</b>	<b>210.68</b>	<b>339.21</b>	<b>5,187.06</b>	<b>898.34</b>	<b>1,133.96</b>	
<b>3. Capital Employed</b>							
a. Specialty Chemicals Business	76,173.81	75,748.93	79,807.08	76,173.81	79,807.08	82,886.89	
b. Pharma Business	54,378.81	51,558.51	32,566.73	54,378.81	32,566.73	38,708.06	
	<b>130,552.62</b>	<b>127,307.44</b>	<b>112,373.81</b>	<b>130,552.62</b>	<b>112,373.81</b>	<b>121,594.95</b>	
<b>4.</b>							
a. Segment Assets	177,869.72			177,869.72			
b. Segment Liabilities	121,913.06			121,913.06			
<b>Total</b>							

Place : Hyderabad  
Date : 14.02.2017

For VIVIMED LABS LIMITED  
(SANTOSH VARALWAR)  
MANAGING DIRECTOR





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA


Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

To  
The Board of Directors  
**VIVIMED LABS LIMITED**  
Hyderabad

**Limited Review Report for the quarter ended 31<sup>st</sup> December, 2016**

1. We have reviewed the accompanying statement of unaudited financial results of M/s. VIVIMED LABS LIMITED for the quarter ended 31<sup>st</sup> December, 2016, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 14<sup>th</sup> February, 2017. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI ( Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05<sup>th</sup> July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

  
P. Murali Mohana Rao  
Partner  
M.No. 023412



Place: Hyderabad  
Date: 14<sup>th</sup> February, 2017